Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Clinical experience with TNF-blockers].

A Forster1, B A Michel

  • 1Rheumaklinik und Institut für Physikalische Medizin Universitätsspital Zürich Gloriastrasse 25 8091 Zürich, Switzerland. adrian.forster@ruz.usz.ch

Zeitschrift Fur Rheumatologie
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stroke recovery patterns and predictors in India: A post-hoc analysis from the ATTEND trial.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2026
Same author

In ovo sexing and genotyping using PCR techniques: a contribution to the 3R principles in chicken breeding.

Scientific reports·2026
Same author

Vaccine microarray patch self-administration: An innovative approach to improve pandemic and routine vaccination rates.

Vaccine·2023
Same author

Evaluation of the self-administration potential of high-density microarray patches to human skin: A preliminary study.

Human vaccines & immunotherapeutics·2023
Same author

Computed diffusion-weighted imaging in patients with transient neurovascular symptoms with and without ischemic infarction.

Journal of neuroradiology = Journal de neuroradiologie·2023
Same author

Awareness, attitudes and acceptability of the HPV vaccine among female university students in Morocco.

PloS one·2022
Same journal

[Prevention strategies in rheumatoid arthritis : From primary prevention to targeted drug interception].

Zeitschrift fur Rheumatologie·2026
Same journal

Methodological concerns and data discrepancies in the indirect treatment comparison of belimumab and anifrolumab.

Zeitschrift fur Rheumatologie·2026
Same journal

Evaluating the comparative efficacy of belimumab vs. anifrolumab in systemic lupus erythematosus: a response.

Zeitschrift fur Rheumatologie·2026
Same journal

[Update: DMARDs for MGUS].

Zeitschrift fur Rheumatologie·2026
Same journal

[A potpourri of diagnoses-Unusual manifestations of a chronic inflammatory bowel disease : Case report].

Zeitschrift fur Rheumatologie·2026
Same journal

[Not measurable but immeasurably important : Fever-The leading symptom of ancient medical theory].

Zeitschrift fur Rheumatologie·2026
See all related articles

New biologic agents, known as TNF blockers, effectively treat rheumatoid arthritis by inhibiting TNF alpha. These agents offer rapid symptom relief, excellent safety, and long-term efficacy, especially for patients unresponsive to traditional therapies.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Context:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and joint destruction.
  • Conventional disease-modifying antirheumatic drugs (DMARDs) are the cornerstone of RA treatment.
  • Tumor necrosis factor (TNF) alpha is a key proinflammatory cytokine implicated in RA pathogenesis.

Purpose:

  • To evaluate the efficacy and safety of biologic agents, specifically TNF blockers, in rheumatoid arthritis treatment.
  • To assess the role of TNF blockers in patients with inadequate response or intolerance to conventional DMARDs.
  • To determine the long-term effectiveness and safety profile of TNF blockers in managing RA disease activity and structural damage.

Summary:

  • Biologic agents, termed TNF blockers, selectively inhibit TNF alpha, a major driver of inflammation in rheumatoid arthritis.

Related Experiment Videos

  • These agents demonstrate significant suppression of disease activity, even in patients who do not respond to conventional DMARDs.
  • TNF blockers show excellent anti-erosive effects, rapid symptom improvement, and good overall safety, enhancing patients' quality of life.

    • Impact:

    • TNF blockers represent a significant advancement in rheumatoid arthritis therapy, offering an effective option for difficult-to-treat patients.
    • The rapid and sustained efficacy, coupled with a favorable safety profile, contributes to improved patient outcomes and quality of life.
    • Due to risks and cost, TNF blockers are recommended for patients with poor response or intolerance to conventional DMARDs, optimizing resource allocation.